Evotec SE reported that Bristol Myers Squibb has exercised its option to enter an exclusive global license agreement covering selected late-stage discovery programs that were developed and progressed within the collaboration. Evotec and BMS originally entered their neurodegeneration partnership in 2016. The initial partnership proved highly productive in generating a promising pipeline of discovery to clinical-stage programs. As such, the companies have extended and expanded the partnership f...